At the news
? NEUTRALIMPACT 5/10 8-K filed May 12, 2026 at 16:10 ET
PepGen reported Q1 2026 net loss of $17.8M ($-0.26/share), narrower than the $30.2M loss in Q1 2025, with cash of $132.3M sufficient into 2H 2027. The FREEDOM2-DM1 5 mg/kg cohort showed favorable safety and efficacy data, the 10 mg/kg cohort is fully enrolled with data expected in 2H 2026, but an FDA partial clinical hold remains unresolved.
- Net loss of $17.8M ($-0.26/share) for Q1 2026 vs $30.2M ($-0.92/share) in Q1 2025
- Cash, cash equivalents and marketable securities of $132.3M as of March 31, 2026
- FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data
- FREEDOM2 10 mg/kg cohort fully enrolled, data on track for 2H 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access